330792-76-2

Basic information

• Product Name: 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine
• Synonyms: 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine;6-phenoxypyridine-3-boronic acid pinacol ester;5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2-phenoxypyridine;2-phenoxypyridine-5-boronic acid Pinacol ester;2-Phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
• CAS NO: 330792-76-2
• Molecular Formula: C17H20BNO3
• Molecular Weight: 297.16
• Mol File: 330792-76-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine(330792-76-2)
• EPA Substance Registry System: 2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine(330792-76-2)

Safety Data

• Hazardous Substances Data: 330792-76-2(Hazardous Substances Data)

Usage

General Description

2-Phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine is a chemical compound that belongs to the class of pyridine derivatives. It is a boron-containing compound and is commonly used in organic synthesis and medicinal chemistry as a reagent and building block for the preparation of various organic compounds. The compound has a unique structure containing a phenoxy group, a tetramethyl dioxaborolane group, and a pyridine ring, making it useful for a wide range of applications in the field of chemical research and drug discovery. Additionally, it is known for its potential biological activity and may have utility in various pharmaceutical and agrochemical applications.

Upstream product

• 766-11-0 5-bromo-2-fluoropyridine 
• 108-95-2 phenol 
• 624-28-2 2,5-dibromopyridine 
• 73183-34-3 bis(pinacol)diborane 
• 59717-96-3 5-bromo-2-phenoxypyridine 

Downstream Products

• 1558038-57-5 C₁₅H₁₁N₅O 

Relevant articles and documents

Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma

Ibrutinib (IBN), a first-in-class BTK-inhibitor, was approved by the FDA for the treatment of mantle cell lymphoma (MCL). Although IBN shows excellent performance as an anti-lymphoma agent, it has some undesirable side effects due to its off-target activities. Our studies yielded a novel series of 3-(6-phenoxypyridin-3-yl)-4-amine-1H-pyrazolo[3,4-d]pyrimidine derivatives capable of potent inhibition of Bruton's tyrosine kinase (BTK). Notably, compound 13e explained potent BTK inhibitory activity and could completely inhibit the phosphorylation of BTK and PLCγ2 in Z138 cells at low micromolar concentration. Compared with IBN, compound 13e improved anti-proliferative activities 3–40 folds in MCL cell lines with IC50 values lower than 1 μM. Low micromolar doses of 13e could induce strong cell apoptosis in Jeko-1 and Z138 cells. In addition, compound 13e showed greater BTK selectivity and higher stability in human liver microsomes than IBN and potential safety improvement for the treatment of MCL.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).